 DURHAM, N.C., Sept. 20, 2021 GLOBE NEWSWIRE -- Humacyte, Inc. Nasdaq: HUMA, a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the issuance of three additional U.S. patents covering its proprietary technology platform. Included in the new patents are additional claims related to the Human Acellular Vessels HAVs, engineered, off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement. New U.S. Patents 10,934,532 and 10,947,498, both titled Tissue-engineered constructs, expand upon existing patents encompassing methods of producing the Companys HAVs and other human tissues, including the scaffolds and methods used to make these product candidates. New U.S. Patent 11,058,534, titled Tubular prothesis, covers biologic replacements for diseased or damaged anatomical conduits, including the trachea. 